Anondita Medicare manufactures male and female condoms and other sexual wellness products for government contracts, private labels, and its own brand, Cobra. The company differentiates itself by building its own production machinery in-house and maintaining integrated packaging facilities.
The company possesses a narrow moat derived from a cost advantage through in-house fabrication of patented production machinery and integrated packaging, which reduces capital expenditure and operating costs. While ROCE is high, the business remains heavily reliant on low-margin government tenders, and the durability of its brand-based moat is yet to be proven against established global competitors.
Management has focused on vertical integration by reinvesting in in-house machine fabrication and expanding capacity to 806 million units. While returns on capital are currently strong, the high level of capital work-in-progress and a shift toward the capital-intensive female condom market represent a significant bet on future demand that has yet to fully materialize in cash flows.
The company's aggressive expansion into capital-intensive female condom production failed to find a private market, leaving expensive machinery idle while government tender cycles lengthened. The high trade receivables and poor cash conversion observed in earlier filings eventually triggered a liquidity crisis when year-end revenue spikes failed to materialize into actual cash. As 'other expenses' continued to balloon, the cost advantage from in-house fabrication was offset by rising operational overhead and the inability to compete with global brands on marketing spend, leading to a permanent contraction in margins and a collapse of the high ROCE narrative.
RichFakir rates Anondita Medicare Ltd's business quality as decent — 67/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Anondita Medicare Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Anondita Medicare Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Anondita Medicare Ltd's fair value is about ₹93 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →